XNAS
PODD
Market cap9.31bUSD
Oct 08, Last price
134.47USD
1D
0.08%
1Q
-16.62%
Jan 2017
256.87%
IPO
770.36%
Name
Insulet Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Key people
President, Chief Executive Officer, Director · since 2025
Dan Manea
Chief Human Resources Officer, Senior Vice President · since 2020
Eric Benjamin
Executive Vice President, Chief Product and Customer Experience Officer · since 2023
Laetitia Cousin
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance · since 2022
John Kapples
Senior Vice President, General Counsel · since 2021
Prem Singh
Senior Vice President - Global Operations · since 2023
Amit Guliani
Acting Chief Technology Officer, Group Vice President - Software Engineering · since 2025
Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller · since 2024
Manoj Raghunandanan
Chief Growth Officer · since 2025
Luciana Borio
Independent Director · since 2021
Independent Director · since 2020
Independent Director · since 2018
Robert Huffines
Independent Director · since 2025
Independent Director · since 2017
Independent Director · since 2024
Timothy Scannell
Independent Chairman of the Board · since 2019
Independent Director · since 2024
Independent Director · since 2022
Legal address
C/O UNITED AGENT GROUP INC.
1521 CONCORD PIKE
SUITE 201
WILMINGTON, DE 19803
US
1521 CONCORD PIKE
SUITE 201
WILMINGTON, DE 19803
US
Headquarters
600 Technology Park Drive
Suite 200
Billerica, MA 01821
US
Suite 200
Billerica, MA 01821
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||